Apolipoprotein C-III is an amyloid-β-binding protein and an early marker for Alzheimer's disease

Yao Hsiang Shih, Kuen Jer Tsai, Chu Wan Lee, Shu Chu Shiesh, Wei Ting Chen, Ming Chyi Pai, Yu Min Kuo

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

It has been demonstrated that peripheral injection of anti-amyloid-β (Aβ) antibodies to patients with Alzheimer's disease (AD) and AD transgenic mice facilitate Aβ clearance. We hypothesized that peripheral circulating Aβ-binding proteins also possess the ability to enhance Aβ clearance and the levels of circulating Aβ-binding proteins could serve as early AD biomarkers. Circulating Aβ-binding proteins were isolated from plasma and identified by LC-MS/MS. Their levels were compared among non-demented individuals without AD family history (ND), with AD family history (ND-FH), and patients with mild AD. The results showed that most of the identified Aβ-binding proteins were apolipoproteins, i.e., apoA-I, apoB-100, apoC-III, and apoE. Aβ bound preferentially to apoA-I-enriched HDL, followed by apoC-III- and apoE-enriched VLDL, and bound less favorably to apoB-100-enriched LDL. Levels of apoA-I were reduced in AD patients and could be used to discriminate AD from ND groups (AUC: 0.93); whereas levels of apoC-III were reduced in both ND-FH and AD groups and could be used to differentiate ND-FH from ND individuals (AUC: 0.81). Both the levels of apoA-1 and apoC-III positively correlated with CASI and MMSE scores. In conclusion, these results suggest that plasma apoA-I could be a sensitive AD biomarker and individuals with low plasma levels of apoC-III are at risk for AD.

Original languageEnglish
Pages (from-to)855-865
Number of pages11
JournalJournal of Alzheimer's disease : JAD
Volume41
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Apolipoprotein C-III
Amyloidogenic Proteins
Carrier Proteins
Alzheimer Disease
Apolipoprotein A-I
Apolipoprotein B-100
Apolipoproteins E
Area Under Curve
Biomarkers
Aptitude
Apolipoproteins
Amyloid
Transgenic Mice

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

@article{29cc42bc9f2d40708a3c8851df07baf0,
title = "Apolipoprotein C-III is an amyloid-β-binding protein and an early marker for Alzheimer's disease",
abstract = "It has been demonstrated that peripheral injection of anti-amyloid-β (Aβ) antibodies to patients with Alzheimer's disease (AD) and AD transgenic mice facilitate Aβ clearance. We hypothesized that peripheral circulating Aβ-binding proteins also possess the ability to enhance Aβ clearance and the levels of circulating Aβ-binding proteins could serve as early AD biomarkers. Circulating Aβ-binding proteins were isolated from plasma and identified by LC-MS/MS. Their levels were compared among non-demented individuals without AD family history (ND), with AD family history (ND-FH), and patients with mild AD. The results showed that most of the identified Aβ-binding proteins were apolipoproteins, i.e., apoA-I, apoB-100, apoC-III, and apoE. Aβ bound preferentially to apoA-I-enriched HDL, followed by apoC-III- and apoE-enriched VLDL, and bound less favorably to apoB-100-enriched LDL. Levels of apoA-I were reduced in AD patients and could be used to discriminate AD from ND groups (AUC: 0.93); whereas levels of apoC-III were reduced in both ND-FH and AD groups and could be used to differentiate ND-FH from ND individuals (AUC: 0.81). Both the levels of apoA-1 and apoC-III positively correlated with CASI and MMSE scores. In conclusion, these results suggest that plasma apoA-I could be a sensitive AD biomarker and individuals with low plasma levels of apoC-III are at risk for AD.",
author = "Shih, {Yao Hsiang} and Tsai, {Kuen Jer} and Lee, {Chu Wan} and Shiesh, {Shu Chu} and Chen, {Wei Ting} and Pai, {Ming Chyi} and Kuo, {Yu Min}",
year = "2014",
month = "1",
day = "1",
doi = "10.3233/JAD-140111",
language = "English",
volume = "41",
pages = "855--865",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

Apolipoprotein C-III is an amyloid-β-binding protein and an early marker for Alzheimer's disease. / Shih, Yao Hsiang; Tsai, Kuen Jer; Lee, Chu Wan; Shiesh, Shu Chu; Chen, Wei Ting; Pai, Ming Chyi; Kuo, Yu Min.

In: Journal of Alzheimer's disease : JAD, Vol. 41, No. 3, 01.01.2014, p. 855-865.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Apolipoprotein C-III is an amyloid-β-binding protein and an early marker for Alzheimer's disease

AU - Shih, Yao Hsiang

AU - Tsai, Kuen Jer

AU - Lee, Chu Wan

AU - Shiesh, Shu Chu

AU - Chen, Wei Ting

AU - Pai, Ming Chyi

AU - Kuo, Yu Min

PY - 2014/1/1

Y1 - 2014/1/1

N2 - It has been demonstrated that peripheral injection of anti-amyloid-β (Aβ) antibodies to patients with Alzheimer's disease (AD) and AD transgenic mice facilitate Aβ clearance. We hypothesized that peripheral circulating Aβ-binding proteins also possess the ability to enhance Aβ clearance and the levels of circulating Aβ-binding proteins could serve as early AD biomarkers. Circulating Aβ-binding proteins were isolated from plasma and identified by LC-MS/MS. Their levels were compared among non-demented individuals without AD family history (ND), with AD family history (ND-FH), and patients with mild AD. The results showed that most of the identified Aβ-binding proteins were apolipoproteins, i.e., apoA-I, apoB-100, apoC-III, and apoE. Aβ bound preferentially to apoA-I-enriched HDL, followed by apoC-III- and apoE-enriched VLDL, and bound less favorably to apoB-100-enriched LDL. Levels of apoA-I were reduced in AD patients and could be used to discriminate AD from ND groups (AUC: 0.93); whereas levels of apoC-III were reduced in both ND-FH and AD groups and could be used to differentiate ND-FH from ND individuals (AUC: 0.81). Both the levels of apoA-1 and apoC-III positively correlated with CASI and MMSE scores. In conclusion, these results suggest that plasma apoA-I could be a sensitive AD biomarker and individuals with low plasma levels of apoC-III are at risk for AD.

AB - It has been demonstrated that peripheral injection of anti-amyloid-β (Aβ) antibodies to patients with Alzheimer's disease (AD) and AD transgenic mice facilitate Aβ clearance. We hypothesized that peripheral circulating Aβ-binding proteins also possess the ability to enhance Aβ clearance and the levels of circulating Aβ-binding proteins could serve as early AD biomarkers. Circulating Aβ-binding proteins were isolated from plasma and identified by LC-MS/MS. Their levels were compared among non-demented individuals without AD family history (ND), with AD family history (ND-FH), and patients with mild AD. The results showed that most of the identified Aβ-binding proteins were apolipoproteins, i.e., apoA-I, apoB-100, apoC-III, and apoE. Aβ bound preferentially to apoA-I-enriched HDL, followed by apoC-III- and apoE-enriched VLDL, and bound less favorably to apoB-100-enriched LDL. Levels of apoA-I were reduced in AD patients and could be used to discriminate AD from ND groups (AUC: 0.93); whereas levels of apoC-III were reduced in both ND-FH and AD groups and could be used to differentiate ND-FH from ND individuals (AUC: 0.81). Both the levels of apoA-1 and apoC-III positively correlated with CASI and MMSE scores. In conclusion, these results suggest that plasma apoA-I could be a sensitive AD biomarker and individuals with low plasma levels of apoC-III are at risk for AD.

UR - http://www.scopus.com/inward/record.url?scp=84929625883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929625883&partnerID=8YFLogxK

U2 - 10.3233/JAD-140111

DO - 10.3233/JAD-140111

M3 - Article

C2 - 24685634

AN - SCOPUS:84929625883

VL - 41

SP - 855

EP - 865

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -